Usher Syndrome Market Report 2026

The usher syndrome market size has grown strongly in recent years. It will grow from $2.24 billion in 2025 to $2.37 billion in 2026 at a compound annual growth rate (CAGR) of 5.7%. The growth in the historic period can be attributed to improved awareness of inherited sensory disorders, expansion of genetic counseling services, availability of advanced diagnostic tools, growth of specialty clinics for rare diseases, increased screening for retinal disorders.

The usher syndrome market size is expected to see strong growth in the next few years. It will grow to $2.94 billion in 2030 at a compound annual growth rate (CAGR) of 5.5%. The growth in the forecast period can be attributed to increasing research into gene therapy solutions, rising investments in rare disease drug development, growing adoption of personalized medicine approaches, expansion of early intervention programs, increasing collaboration between research institutions and healthcare providers. Major trends in the forecast period include increasing adoption of genetic testing for early diagnosis, growing focus on gene-based therapeutic approaches, rising use of advanced diagnostic imaging tools, expansion of multidisciplinary treatment pathways, enhanced patient monitoring and disease management models.

The increasing prevalence of inherited disorders is expected to drive the growth of the usher syndrome market in the coming years. Inherited disorders are genetic conditions transmitted from parents to children through DNA, often resulting from mutations in one or more genes. The incidence of these disorders is rising due to factors such as increasing parental age, leading to a higher occurrence of genetic conditions in newborns. Usher syndrome, being a genetic disorder, requires early diagnosis, specialized care, and targeted treatment approaches. Greater awareness and screening for genetic disorders are identifying more cases of Usher syndrome, thereby increasing the demand for diagnostic tests, genetic counseling, and therapeutic interventions. For example, in February 2023, the World Health Organization, a Switzerland-based international public health agency of the United Nations, reported that congenital disorders were responsible for approximately 240,000 newborn deaths worldwide within the first 28 days of life each year, along with an additional 170,000 deaths among children aged 1 month to 5 years. Therefore, the rising prevalence of inherited disorders is anticipated to fuel the growth of the usher syndrome market.

Key companies in the usher syndrome market are focusing on clinical studies to develop gene therapies and innovative treatments that can slow or reverse vision and hearing loss. These studies aim to improve early diagnosis, enhance assistive technologies, and explore potential drug-based interventions for better disease management. For instance, in October 2024, AAVantgarde Bio, an Italy-based biotechnology company, initiated the LUCE-1 trial, a Phase I/II clinical study to evaluate the safety and efficacy of its gene therapy, AAVB-081, for treating retinitis pigmentosa associated with Usher Syndrome type 1B (USH1B). The LUCE-1 trial is designed to assess the safety and tolerability of AAVB-081, which delivers a functional copy of the MYO7A gene essential for retinal health.

In December 2023, Laboratoires Théa, a France-based pharmaceutical company, acquired sepofarsen and ultevursen from ProQR Therapeutics for an undisclosed amount. This acquisition is intended to allow Laboratoires Théa to advance the clinical development of sepofarsen and ultevursen for the treatment of inherited retinal diseases, including LCA10 and Usher syndrome 2A. ProQR Therapeutics NV, based in the Netherlands, is a biotechnology company focused on developing treatments for Usher syndrome type 2.

Major companies operating in the usher syndrome market are Cochlear Ltd, Advanced Bionics AG, Spark Therapeutics, Editas Medicine Inc, ProQR Therapeutics NV, Odylia Therapeutics, ReNeuron Group plc, Sensorion SAS, Gensight Biologics, AAVantgarde Bio, Laboratoires Théa, Atsena Therapeutics, Nanoscope Therapeutics, Nacuity Pharmaceuticals, Janus Biotechnology, Eiger BioPharmaceuticals, Audentes Therapeutics, Sarepta Therapeutics, Regeneron Pharmaceuticals, Amgen, Alnylam Pharmaceuticals, UniQure.

North America was the largest region in the usher syndrome market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the usher syndrome market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the usher syndrome market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the usher syndrome market by increasing the cost of imported genetic testing kits, diagnostic imaging equipment, specialized laboratory reagents, and medical devices used in disease management. Hospitals and specialty clinics in North America and Europe are most affected due to reliance on imported advanced diagnostics, while Asia-Pacific faces higher costs for research equipment and reagents. These tariffs are contributing to higher diagnostic and treatment expenses and slowing technology adoption. However, they are also encouraging localized diagnostic manufacturing, regional laboratory expansion, and domestic research initiatives focused on rare genetic disorders.

The usher syndrome market research report is one of a series of new reports that provides usher syndrome market statistics, including usher syndrome industry global market size, regional shares, competitors with a usher syndrome market share, detailed usher syndrome market segments, market trends and opportunities, and any further data you may need to thrive in the usher syndrome industry. This usher syndrome market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Usher syndrome is a genetic condition that impacts both hearing and vision, often resulting in deafness or hearing impairment and a progressive eye disorder called retinitis pigmentosa (RP). It is the leading cause of combined deaf-blindness and is inherited in an autosomal recessive manner.

The primary types in the Usher syndrome market include type 1, type 2, type 3, and other types. Type 1 Usher syndrome is the most severe form, marked by profound deafness from birth, significant balance problems, and early-onset vision loss caused by retinitis pigmentosa (RP). Treatments encompass devices, medications, therapies, and other interventions, while diagnostic methods include electroretinogram, optical coherence tomography, videonystagmography, audiology, genetic testing, and other diagnostic approaches. Distribution channels include hospital pharmacies, retail pharmacies, and others, with end users comprising hospitals, specialty clinics, and others.

The usher syndrome market consists of revenues earned by entities by providing services such as audiology services, vision rehabilitation, genetic counseling, and mobility training. The market value includes the value of related goods sold by the service provider or included within the service offering. The usher syndrome market also includes sales of hearing aids, cochlear implants, assistive listening devices, and low-vision aids. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.